These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 4704396)

  • 1. [Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine)].
    Campanella G; Carrieri P; Romito D; Pasqual-Marsettin E
    Acta Neurol (Napoli); 1973; 28(1):1-34. PubMed ID: 4704396
    [No Abstract]   [Full Text] [Related]  

  • 2. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W; Linauer W; Mentasti M; Riederer P
    Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
    [No Abstract]   [Full Text] [Related]  

  • 3. [Psychologic evaluation of amantadine treatment of parkinsonism and comparative analysis of the effects with L-dopa].
    Puca FM; Micalizzi V; Megna GF; Barbieri NF; Pigneri MT
    Acta Neurol (Napoli); 1971; 26(6):707-30. PubMed ID: 4946491
    [No Abstract]   [Full Text] [Related]  

  • 4. [Studies of the effect of I-adamantyl-amine hydrochloride and of L-dopa with Ro 4-4602 in human catatonia].
    Megna GF; Specchio LM
    Acta Neurol (Napoli); 1973; 28(5):566-72. PubMed ID: 4789495
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of parkinsonism using L-dopa. I].
    Glass J
    Z Arztl Fortbild (Jena); 1972 Dec; 66(23):1195-9. PubMed ID: 4652156
    [No Abstract]   [Full Text] [Related]  

  • 6. The treatment of parkinsonism with L-Dopa and amantadine.
    Green J
    J Fla Med Assoc; 1970 Jun; 57(6):28-33. PubMed ID: 5445813
    [No Abstract]   [Full Text] [Related]  

  • 7. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM; Megna GF; Masi G; Specchio LM
    Riv Patol Nerv Ment; 1974 Oct; 95(5):676-84. PubMed ID: 4470268
    [No Abstract]   [Full Text] [Related]  

  • 8. [The addition of amantadine to prolonged treatment with L-Dopa. Considerations on 20 cases].
    Giuffrè R; Gambacorta D
    Minerva Med; 1971 Oct; 62(82):4009-12. PubMed ID: 5125066
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E; Cerillo A; Tata MR; Decina A
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 11. [6 months of treatment with amantadine and L-Dopa. Comparison in 2 groups of patients with parkinsonism].
    Buscaino GA; Campanella G; Zallone E
    Minerva Med; 1971 Oct; 62(82):3974-8. PubMed ID: 5125057
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of leukeran on iron, copper, transferrin and ceruloplasmin levels in blood serum in systemic scleroderma after long-term treatment].
    Olszewska Z; Dudek H
    Reumatologia; 1979; 17(2):167-73. PubMed ID: 472527
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

  • 14. A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).
    Merrick EM; Schmitt PP
    Curr Ther Res Clin Exp; 1973 Aug; 15(8):552-8. PubMed ID: 4200529
    [No Abstract]   [Full Text] [Related]  

  • 15. L-dopa for parkinsonism.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
    [No Abstract]   [Full Text] [Related]  

  • 16. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 17. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C; Romero S; Gomensoro JB
    Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa and amantadine in the treatment of Parkinsonism.
    Critchley E
    Practitioner; 1972 Apr; 208(246):499-504. PubMed ID: 5031037
    [No Abstract]   [Full Text] [Related]  

  • 19. [Action of amantadine HCl alone and in combination with L-dopa on parkinsonism].
    Danielczyk W; Korten JJ
    Med Monatsschr; 1971 Oct; 25(10):472-9. PubMed ID: 5122447
    [No Abstract]   [Full Text] [Related]  

  • 20. [Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
    Dietrichson P
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2113-5. PubMed ID: 4590070
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.